Topline data were announced from a phase 2/3 trial evaluating tovecimig plus paclitaxel in patients with advanced biliary tract cancer.

ETHealthworld.com brings latest breast cancer drug news, views and updates from all top sources for the Indian Health industry.

BRIDGEWATER, N.J. and BENGALURU, India, April 10, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the ...

Find Breast Cancer Recurrence Latest News, Videos & Pictures on Breast Cancer Recurrence and see latest updates, news, information from NDTV.COM. Explore more on Breast Cancer Recurrence.

The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

The EC based its decision on data from the DESTINY-Breast06 trial, which included patients whose tumors had very low levels of HER2 expression.

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

Kaplan–Meier curves showed that extended adjuvant pyrotinib administered after trastuzumab-based adjuvant therapy provides a promising survival benefit in patients with high-risk HER2-positive breast ...